EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity

Iseulys Richert, Lionel Chalus, Benoit Pinteur, Paul Bravetti iD, Corinne Tortorelli, George Alzeeb, François Ghiringhelli iD

Cells · 22.04.2026 · 15 (9) · 741

DOI: 10.3390/cells15090741 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 22.04.2026. Verfasst von Iseulys Richert und 6 weiteren Autor:innen. Beteiligte Einrichtung: Brenus-Pharma, 69002 Lyon, France. Hauptthemen laut MEDLINE: Haptens, Immunotherapy, Neoplasms. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hapten-based immunotherapies represent a promising strategy to enhance the immunogenicity of tumor antigens and promote antitumor immune responses. Chemical conjugation of small haptens to antigens generates novel antigenic determinants that increase immune recognition. Mechanistic studies indicate that haptenation enhances antigen uptake, dendritic cell maturation, and the activation of both cellular and humoral immunity. In preclinical models, hapten-modified antigens induce robust immune activation, tumor regression, and durable immune memory. Clinically, dinitrophenyl-modified autologous tumor cell vaccines elicit delayed-type hypersensitivity responses and clonal T-cell expansion, with evidence of clinical activity and a favorable safety profile. However, their clinical benefit remains to be confirmed in larger, randomized studies. Emerging strategies include in situ haptenation and bihaptenized or stressed hapten-modified allogeneic platforms, which aim to expand epitope diversity and enhance immune priming. Hapten-based immunotherapies offer a clinically feasible approach to converting poorly immunogenic tumors into effective immune targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HaptensImmunotherapyNeoplasmsHumansAnimalsCancer VaccinesAntigens, NeoplasmDendritic Cells

Stichwörter der Autor:innen

delayed-type hypersensitivitydendritic cellshaptenationimmunotherapiestumor-associated antigens

Substanzen

HaptensCancer VaccinesAntigens, Neoplasm

Autor:innen und Institutionen

  • Brenus-Pharma, 69002 Lyon, France.
  • University of Bourgogne Franche-Comté, 21000 Dijon, France.
  • Department of Medical Oncology, Centre Georges-François Leclerc, 21000 Dijon, France.
  • Centre de Recherche INSERM LNC-UMR1231, 21000 Dijon, France.

ORCID-Profile: Paul Bravetti, François Ghiringhelli

Zitieren

APA

Richert, I., Chalus, L., Pinteur, B., Bravetti, P., Tortorelli, C., Alzeeb, G., & Ghiringhelli, F. (2026). Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity. Cells, 15(9), 741. https://doi.org/10.3390/cells15090741

Vancouver

Richert I, Chalus L, Pinteur B, Bravetti P, Tortorelli C, Alzeeb G, et al. Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity. Cells. 2026;15(9):741. doi:10.3390/cells15090741

BibTeX
@article{Richert2026,
  author = {Richert, Iseulys and Chalus, Lionel and Pinteur, Benoit and Bravetti, Paul and Tortorelli, Corinne and Alzeeb, George and Ghiringhelli, François},
  title = {Hapten-Based Cancer Immunotherapy: From Immune Activation to Antitumor Activity},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {9},
  pages = {741},
  doi = {10.3390/cells15090741}
}
Kostenlos starten →